Structural and molecular details of an anti-fungal target's interaction with inhibitors suggest ways to design better treatments for fungal infections.

New findings add to the understanding of how the enzyme COX-2 works, which is critical to the development of COX-2-targeted anti-inflammatory drugs.

Two Vanderbilt-Ingram Cancer Center (VICC) investigators — Jennifer Pietenpol, Ph.D., B.F. Byrd Jr. Professor of Oncology and director of VICC, and Valerie Jansen, M.D., Ph.D., medical oncology fellow — have received new cancer research grants awarded by Susan G. Komen, the world’s largest nonprofit funder of breast cancer research.

Vanderbilt-Ingram Cancer Center (VICC) has been recognized for the impact of its research programs and excellence in patient care by a panel of National Cancer Institute (NCI) reviewers, receiving an overall “exceptional” score as part of the renewal of the Cancer Center Support Grant (CCSG).

Vanderbilt investigators have developed a framework for studying cellular responses that could be used to identify the agents driving a range of biological processes in health and disease.

Vanderbilt investigators have discovered how mammals, including humans, produce the painkiller morphine.

Vanderbilt researchers are exploring how neuroblastoma tumors begin and progress, knowledge that could provide new treatments for this pediatric cancer.